Key Points Annovis received a U.S. patent covering buntanetap Form B, the crystalline form used in its ongoing Alzheimer’s and Parkinson’s studies. The patent covers…
November 13, 2026
November 12, 2026
NervGen Wins FDA Breakthrough Therapy Designation for Spinal Cord Injury Drug as Phase 3 Enrollment Advances
Key Points NervGen received FDA Breakthrough Therapy designation for NVG-291 in chronic traumatic cervical motor-incomplete spinal cord injury. The decision followed FDA review of safety…
November 11, 2026
NRx Pharma Begins Ketamine Sales Push, Targeting January 2027 Shipments and Margins Above 50%
Key Points NRx has launched commercial outreach for its U.S.-made, preservative-free ketamine, with initial supply agreements and preorders targeted for late 2026. Product shipments are…
Key Points Abeona acquired Ellodi Pharmaceuticals’ APT-1011, renamed ABO-801, for $20 million in common stock and potential future payments. The once-daily dissolving tablet is being…
Key Points LifeMD’s affiliated pharmacy can directly dispense and ship Lilly’s Zepbound and Foundayo to eligible patients nationwide. Patients can purchase prescribed medicines through LifeMD…
Key Points Opus Genetics completed dosing in all 11 participants in Cohort 2 of its Phase 1/2 BIRD-1 trial. The cohort received OPGx-BEST1 at three…
Key Points EB-003 altered brain-wave activity in prefrontal and parietal cortical regions in mice, supporting functional activity in the central nervous system. Its profile differed…
Key Points Ardelyx has fully enrolled its Phase 3 ACCEL trial evaluating IBSRELA in adults with chronic idiopathic constipation, or CIC. The study compares twice-daily…
Key Points Rhythm will replace its low-to-mid-single-digit royalty structure with a 1% royalty on global net sales across its MC4R portfolio, including setmelanotide, bivamelagon and…
November 02, 2026
Compass Pathways and DBSA Survey Highlights Burden of Treatment-Resistant Depression
Key Points A national survey included 261 people living with treatment-resistant depression and 73 caregivers. Some 95% of surveyed patients described themselves as functioning but…
November 02, 2026
Actuate Receives U.S. Patent Allowance for Elraglusib Oral Tablets Ahead of Planned Trial
Key Points The USPTO issued a Notice of Allowance for claims covering oral tablet compositions of elraglusib, Actuate’s investigational GSK-3β inhibitor. The allowance includes the…
Key Points Hims & Hers reported accelerating domestic revenue growth and international expansion, while raising its 2026 revenue outlook. Management reiterated 2030 targets of at…